News
4.2.2 Sacituzumab govitecan and Pembrolizumab in triple-negative breast cancer (TNBC) In a Phase I/II clinical trial exploring Sacituzumab govitecan, an ADC targeting Trop-2, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback